Navigation Links
Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
Date:9/24/2007

PRINCETON, N.J., Sept. 24 /PRNewswire-FirstCall/ -- Novo Nordisk, a world leader in diabetes care, announced that effective today, the company is listed in the Dow Jones Sustainability World Index (DJSI World) as best-in-class in the healthcare industry -- one of 18 global supersectors analyzed.

The latest global analysis of corporate sustainability leadership was based on a thorough analysis of companies' economic, environmental and social performance, assessing issues including corporate governance, risk management, branding, climate change, supply chain standards and labor practices.

The report concludes "Novo Nordisk is the leading company in terms of sustainability in the pharmaceutical industry. Sustainability is an integral part of its corporate strategy and business organization."

The report continues, "Novo Nordisk is particularly strong in the social dimension where it achieved the industry top ratings in human capital development, corporate citizenship/philanthropy, and social reporting." The company's responsible sourcing, environmental management, bioethics and climate strategy also achieve high scores.

"This honor provides us further encouragement for operating our business according to our Triple Bottom Line philosophy -- a company that can be economically vital, as well as socially and environmentally responsible," said Martin Sorters, president, Novo Nordisk in the United States.

"Our passion for changing diabetes is supported by an understanding that sustainability in business is not just possible but necessary. By putting the patient at the center of all we do -- from providing the best therapies to patients and advocating our employees' volunteerism with patient groups and at diabetes camps to our environmental stewardship through water conservation efforts and our climate change strategy -- we strive to be successful and responsible."

The indexes, which currently comprise USD$5.6 billion assets under management, are used as a tool by asset managers in 15 countries to guide their investment decisions.

Novo Nordisk has been a component of the Dow Jones Sustainability Indexes every year since the launch in 1999.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.

Further information:

Media: Investors:

Sean Clements Christian Qvist Frandsen

Tel: 609 514 8316 Tel: 609 919 7937

secl@novonordisk.com cqfr@novonordisk.com


'/>"/>
SOURCE Novo Nordisk
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ontario Ranks Highest in Free Bird Flu Vaccination Rates
2. Imbalance In Gender Ratio Addressed By Religious Leaders
3. Religious Leaders condemn determination of sex in hospitals
4. Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare
5. North-Eastern Leaders Of India Meet To Discuss HIV Problems
6. Cheerleaders run high risk of injury-US study
7. Muslim Leaders’ Help Sought To Discourage Smokin
8. India needs dental health leadership, says expert
9. Freedom Fighter And Orissa Congress Leader Dies Of Chest Pain
10. Religious Leaders Come In The Way Of Euthanasia
11. Learn From a Leader: Smitherman shares a personal story about his battle with drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles ... minutes later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised ... teen the hospital’s 30th heart transplant recipient. , “He was playing at home, when ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... One of ... changing of the securement tape is painful for her. "This is why the co-inventor ... patients’ heads," she said. , They then created a prototype of the patent-pending AV-AIR, ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... Studio City, CA (PRWEB) , ... December 07, 2016 , ... ... number during the holidays and winter seasons. One major study analyzing heart attacks ... January compared to August of a given year. We would all agree of course–no ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who believe ... hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh Sheets, ... that you could reach out for, and grab, on the old carousels. If ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 ... II trial in patients with unresectable malignant pleural ... survival (PFS). The data, presented at the 17 ... in Vienna , showed nintedanib ... to placebo plus pemetrexed/cisplatin, with a significantly improved ...
(Date:12/7/2016)... YORK , December 7, 2016 ... Pharmaceuticals PLC (NASDAQ: JAZZ ), Anthera Pharmaceuticals Inc. ... DNAI ), and AveXis Inc. (NASDAQ: AVXS ... Sector Index fell roughly 37% to reach a level equal ... it is down by approximately 14% for the year, it ...
Breaking Medicine Technology: